Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT02483650
Other study ID # CDR004
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date January 2005

Study information

Verified date April 2018
Source U.S. Wound Registry
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world patient outcome and side effect information from electronic health records submitted to a specialty specific hyperbaric registry as part of "Stage 2 of Meaningful Use," including data provided to meet PQRS requirements via the registry's QCDR mission.

Goals include understanding the value of HBOT among patients treated for a variety of conditions in relation to the frequency and severity of HBOT side effects. While randomized, controlled trials can establish the efficacy of treatments like HBOT, because they routinely exclude patients with co-morbid conditions common to those patients seen in usual clinical practice, the results of RCTs are usually non-generalizable. Real world data can be used to better understand the effectiveness of HBOT among typical patients, as well as the risks associated with treatment.


Description:

The goal of the Hyperbaric Oxygen Therapy Registry (HBOTR) for Wounds is to provide comparative effectiveness data for patients and to understand whether clinical practice guidelines are followed in the use of HBOT.

Hyperbaric Oxygen Therapy (HBOT) is the use of oxygen at greater than one atmosphere (sea level) pressures and is administered by placing the entire patient in a pressurized vessel and having the patient breathe 100% oxygen. The minimum treatment pressure with evidence to support its use among the conditions approved by the Undersea and Hyperbaric Medical society is 2.0 atmospheres absolute (2 ATA) which is an inspired partial pressure of oxygen of approximately 1,520 mmHg. Hyperbaric treatments which provide less than 100% inspired oxygen at the treatment pressure and/or which provide an inspired partial pressure of oxygen less than 760 mmHg are not hyperbaric therapy. Topically applied oxygen is not hyperbaric oxygen therapy. Oxygen is a drug with a well-defined dose response curve as well as acute and chronic drug effects. HBOT also has side effects including oxygen toxicity to many organ systems. The physiological effects of hyperbaric oxygen therapy are well studied. Effectiveness in real world patients is the best current option to understand the role of HBOT in wound healing.

Hospital based outpatient wound centers participating in the US Wound Registry agree to provide data as part of quality initiatives and to meet their Stage 2 Meaningful use criteria. The HBOTR is a subset of the USWR (Chronic Disease Registry) data. All patient data from all participating hyperbaric centers are transmitted to the USWR where data are then used as designated for benchmarking, to satisfy the requirements of PQRS for advanced practitioners, and for data needed by the UHMS to respond to governmental agencies. Data used for effectiveness research are HIPAA de-identified.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 5000
Est. completion date
Est. primary completion date January 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients receiving Hyperbaric Oxygen Therapy for any UHMS Approved indication

Exclusion Criteria:

Study Design


Related Conditions & MeSH terms

  • Acute Thermal Burn Injury
  • Air or Gas Embolism
  • Burns
  • Carbon Monoxide Poisoning
  • Clostridial Myositis and Myonecrosis (Gas Gangrene)
  • Compartment Syndromes
  • Compromised Grafts and Flaps
  • Crush Injuries
  • Crush Injury, Compartment Syndrome & Other Acute Traumatic Ischemias
  • Decompression Sickness
  • Delayed Radiation Injury (Soft Tissue and Bony Necrosis)
  • Embolism
  • Embolism, Air
  • Gangrene
  • Gas Gangrene
  • Hearing Loss
  • Hearing Loss, Sensorineural
  • Idiopathic Sudden Sensorineural Hearing Loss
  • Intracranial Abscess
  • Ischemia
  • Myositis
  • Necrosis
  • Necrotizing Soft Tissue Infections
  • Osteomyelitis
  • Osteomyelitis (Refractory)
  • Peripheral Arterial Insufficiency and Central Retinal Artery Occlusion
  • Poisoning
  • Radiation Injuries
  • Retinal Artery Occlusion
  • Severe Anemia
  • Soft Tissue Infections
  • Wounds and Injuries

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
U.S. Wound Registry Undersea and Hyperbaric Medical Society (UHMS)

Outcome

Type Measure Description Time frame Safety issue
Other Complications or Side Effects among patients undergoing Treatment with HBOT Scores in % of: otic barotrauma, other barotrauma, central nervous system oxygen toxicity, confinement anxiety, pneumothorax, sudden respiratory distress, visual acuity changes, low blood sugar, and pulmonary oxygen toxicity. 12 months
Other Appropriate use of HBOT in patients treated for a Diabetic foot ulcer Score in % of cases with appropriate use 12 Months
Primary Outcome of problem treated with HBOT Counts by outcome type 12 Months
Secondary Major Amputation in Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers Treated with HBOT Scored in % of major amputations 12 Months
Secondary Preservation of Function with a minor amputation among patients with Wagner Grade 3, 4, or 5 Diabetic Foot Ulcers Treated with HBOT Scored in % of minor amputations 12 Months
See also
  Status Clinical Trial Phase
Completed NCT03669848 - Is Transcutaneous Carbon Monoxide Saturation of E-cigarette Users Comparable to That of Smokers?
Completed NCT04656912 - Hyperbaric Oxygen Therapy Initiation Time in Acute Carbon Monoxide Poisoning
Recruiting NCT04975867 - Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning N/A
Terminated NCT01100515 - Hyperbaric Oxygen Therapy for Acute Domestic Carbon Monoxide (CO) Poisoning Phase 3
Terminated NCT01099995 - Hyperbaric Oxygen Therapy for Comatose Patients With Acute Carbon Monoxide Poisoning Phase 3
Terminated NCT03017742 - Utility of Non-invasive Carboxyhemoglobin and Total Hemoglobin Measurement in the Emergency Department
Terminated NCT01059708 - Outcome Following Carbon Monoxide Poisoning in Children N/A
Recruiting NCT05591300 - Microparticles Blood Level in Acute Carbon Monoxide Poisoning
Not yet recruiting NCT04475263 - Cognitive and Blood Biomarker Assessment After CO Exposure
Completed NCT03926494 - Carbon Monoxide-induced Coma: Prognostic Factors
Recruiting NCT02375126 - Normal Quantitative EEG (qEEG) Dataset
Completed NCT03342209 - Utility of High Flow Nasal Cannula in CO Toxicity N/A
Completed NCT00465855 - One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning Phase 4
Recruiting NCT04490317 - CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Withdrawn NCT04118491 - Hyperbaric Oxygen for Carbon Monoxide Induced Chronic Encephalopathy N/A
Unknown status NCT00841165 - Carbon Monoxide Monitoring and Emergency Treatment N/A
Withdrawn NCT00280579 - Cyanide Poisoning in Fire Victims N/A
Completed NCT05088005 - Prognostic Biomarkers in CO Poisoning
Completed NCT03030833 - Dysfunctional Hemoglobin Pulse Oximetry N/A
Recruiting NCT02860455 - Role of Pulse Co-oximetry for Detecting Carbon Monoxide Poisoning in the Prehospital Emergency Medical Service Setting N/A